Interview with the Expert: Dr. Peter YM Woo - Glioblastoma Multiforme (GBM) Treatment with Combination of TTFields and Chemotherapy: When and Where to Implement TTFields in the Clinical Setting?
Currently, the standard of care for patients with glioblastoma multiforme (GBM) consists of surgical resection or biopsy followed by adjuvant concurrent chemo-radiotherapy (CCRT) with temozolomide.1 To further improve the clinical course of GBM patients, tumor-treating fields (TTFields) were introduced as a concurrent antimitotic treatment to CCRT and had demonstrated significant survival benefit among GBM patients in the EF-14 study.1 Importantly, a subgroup analysis of the EF-14 study among Asian patients demonstrated that TTFields had significantly improved the 1-year survival rate of GBM patients to 96% when compared to 73% in those receiving temozolomide only (p=0.033).2 In a recent interview with Omnihealth Practice, Dr. Woo Yat Ming, Peter, Associate Consultant, Department of Neurosurgery, Kwong Wah Hospital, discussed the clinical application of TTFields in Hong Kong population and reviewed the safety and efficacy of the novel treatment strategy in the local setting.
This is an independent editorial material, published and distributed through unrestricted educational support from Zai Lab (Hong Kong) Limited, for the purpose of continuing medical education only.
Stupp R et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017 Dec 19;318(23):2306-16.
Kim CY et al. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial. J Neurooncol. 2020 Feb;146(3):399-406.